Physician profile
Mukta Gupta
NPI 1689673873
$12,995.77
in general payments reported to CMS, 2019-2025
46 companies · $1,853 in 2025
The $1,853 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,783 · 2020: $1,797 · 2021: $2,826 · 2022: $1,636 · 2023: $1,691 · 2024: $1,409 · 2025: $1,853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,952.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,649.16 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $1,544.94 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $904.68 | 2019-2025 | Synjardy, Jardiance, Spiriva Respimat |
| Novo Nordisk INC | $895.52 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $690.41 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $646.00 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $611.19 | 2019-2022 | |
| Pfizer INC. | $567.31 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $522.13 | 2019-2024 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $426.01 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $417.00 | 2019-2025 | Gardasil 9, Vaqta, Steglatro |
| Takeda Pharmaceuticals U.S.A., INC. | $244.04 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $229.48 | 2019-2022 | |
| Astellas Pharma US INC | $202.45 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $187.64 | 2025 | Caplyta |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $177.25 | 2019 | |
| Novartis Pharmaceuticals Corporation | $175.73 | 2019-2022 | |
| Amarin Pharma, INC. | $175.33 | 2020-2022 | |
| Verona Pharma, INC. | $155.28 | 2025 | Ohtuvayre |
| Corium, LLC | $138.82 | 2023-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $135.20 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $125.15 | 2019-2024 | Eliquis |
| Alnylam Pharmaceuticals INC. | $124.71 | 2024-2025 | Givlaari |
| Xeris Pharmaceuticals, INC. | $108.55 | 2021-2025 | Gvoke Hypopen |
| Teva Pharmaceuticals USA, INC. | $104.14 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.67 | 2022-2025 | |
| Abbott Laboratories | $74.88 | 2021-2024 | Freestyle Libre 2 |
| Allergan, INC. | $73.69 | 2019-2020 | |
| Exact Sciences Corporation | $72.04 | 2025 | The Cologuard Plus Collection Kit |
| Lundbeck LLC | $59.94 | 2022-2025 | Rexulti |
| Collegium Pharmaceutical, INC. | $59.55 | 2025 | Jornay Pm |
| Sanofi Pasteur INC. | $49.63 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.49 | 2023-2024 | Xifaxan, Trulance |
| Sobi, INC | $43.64 | 2023 | |
| Horizon Therapeutics Plc | $41.07 | 2021-2022 | |
| Dexcom, INC. | $39.22 | 2024 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $33.93 | 2025 | Auvelity |
| Amgen INC. | $30.36 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $24.35 | 2022 | |
| Owp Pharmaceuticals, INC. | $19.02 | 2023 | Subvenite, Lamotrigine |
| Biohaven Pharmaceuticals, INC. | $17.86 | 2021 | |
| Exeltis, USA INC. | $15.20 | 2024 | Slynd |
| Eisai INC. | $14.84 | 2022 | |
| Circassia INC. | $13.66 | 2019 | |
| Adlon Therapeutics L.P. | $13.47 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $13.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mukta Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.